Clinical Study of Rituximab Combined with Chemotherapy in the Treatment of Lymphoma with Hypergammaglobulinemia

To further evaluate the clinical influencing factors of rituximab in treatment diffuse large B cell lymphoma patients with hypergammaglobulinemia by studying efficacy combined chemotherapy hypergammaglobulinemia. 89 treated our hospital from January 2011 to December 2020 were selected as subjects. After informed consent, control group divided into two groups: was conventional and on basis chemotherapy. Basic information such age, sex, past medical history, tumor stage so collected. The venous blood collected before after levels hemoglobin, erythrocyte sedimentation rate, albumin, globulin, Lactate dehydrogenase beta 2-microglobulin measured automatic biochemical analyzer Immunoglobulin G, A M immunoturbidimetry. Complete remission, partial response, stable disease progression, recorded total effective rate calculated. There 27 (14 males 13 females, 9 hyperimmunoglobulinemia), according Ann Arbor staging, there 1 case I, 10 cases II, 7 III IV. 62 group, aged 56.3±14.2 y, including 25 37 18 hyperimmunoglobulinemia 16 29 no significant difference incidence hyperimmunoglobulinemia, International prognostic index score, previous history between groups. lactate treatment. lower than that statistically (p<0.05). ImmunoglobulinA, ImmunoglobulinM globulin treatment, but level significantly chemotherapy, ImmunoglobulinG, those while ImmunoglobulinA 82.3 %, which much higher (55.6 %) In 85.4 normal (26.8 Rituximab is B-cell It can effectively reduce immunoglobulin vivo provide reference for